# DMK PHARMACEUTICALS Corp

DMK PHARMACEUTICALS Corp is a company headquartered in San Diego, CA, United States.

## Company overview

- **Legal name:** DMK PHARMACEUTICALS Corp
- **Former names in filing history:** Adamis Pharmaceuticals Corp (2009-04-08 to 2023-09-01); CELLEGY PHARMACEUTICALS INC (1996-07-09 to 2009-04-03)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** San Diego, CA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0000887247

## About

DMK PHARMACEUTICALS Corp is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0000887247, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2023-03-16, it reported annual revenue of USD 4,756,078; net income of USD -26,478,273; total assets of USD 10,930,840 for the fiscal period ended 2022-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2022 (period ended 2022-12-31)

- **Revenue:** $4.8M (USD 4,756,078)
- **Net income:** -$26.5M (USD -26,478,273)
- **Total assets:** $10.9M (USD 10,930,840)
- **Cash and equivalents:** $1.1M (USD 1,081,364)
- **Operating cash flow:** -$25.9M (USD -25,900,506)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $2.2M (USD 2,208,680)
- **Net income:** -$45.8M (USD -45,828,198)
- **Total assets:** $38.3M (USD 38,297,987)
- **Cash and equivalents:** $23.2M (USD 23,220,770)
- **Operating cash flow:** -$37.8M (USD -37,785,297)

### FY2020 (period ended 2020-12-31)

- **Revenue:** $16.5M (USD 16,527,397)
- **Net income:** -$49.4M (USD -49,391,089)
- **Total assets:** $30.9M (USD 30,867,462)
- **Cash and equivalents:** $6.9M (USD 6,855,355)
- **Operating cash flow:** -$20.9M (USD -20,901,360)
- **Later filings:** Revenue, Cash and equivalents: shown as originally filed; later filings report different values for the same periods.

### FY2019 (period ended 2019-12-31)

- **Revenue:** $22.1M (USD 22,113,869)
- **Net income:** -$29.3M (USD -29,306,769)
- **Total assets:** $47.8M (USD 47,840,517)
- **Cash and equivalents:** $8.8M (USD 8,810,636)
- **Operating cash flow:** -$19.9M (USD -19,885,668)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2024-07-01 — period 2024-05-16 — CURRENT REPORT
- Form 8-K — filed 2024-02-07 — period 2024-02-06 — CURRENT REPORT
- Form 8-K — filed 2024-02-05 — period 2024-02-02 — CURRENT REPORT
- Form 8-K — filed 2024-01-31 — period 2024-01-25 — CURRENT REPORT
- Form 8-K — filed 2024-01-23 — period 2024-01-22 — CURRENT REPORT
- Form 8-K — filed 2024-01-03 — period 2023-12-28 — CURRENT REPORT
- Form 8-K — filed 2024-01-03 — period 2024-01-03 — CURRENT REPORT
- Form 8-K — filed 2023-12-21 — period 2023-12-15 — CURRENT REPORT
- Form 8-K — filed 2023-12-04 — period 2023-11-30 — CURRENT REPORT
- Form 8-K — filed 2023-11-28 — period 2023-11-21 — CURRENT REPORT
- Form 8-K — filed 2023-11-15 — period 2023-11-09 — CURRENT REPORT
- Form 8-K — filed 2023-11-14 — period 2023-11-14 — CURRENT REPORT

---

Updated: 2026-10-23T20:12:17Z

Canonical page: https://altss.com/profile/dmk-pharmaceuticals-corp

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology